title: OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.
abstract: Biofilm growth is a universal survival strategy for bacteria, providing an effective and resilient approach for survival in an otherwise hostile environment. In the context of an infection, a biofilm provides resistance and tolerance to host immune defenses and antibiotics, allowing the biofilm population to survive and thrive under conditions that would destroy their planktonic counterparts. Therefore, the disruption of the biofilm is a key step in eradicating persistent bacterial infections, as seen in many types of chronic disease. In these studies, we used both in vitro minimum biofilm eradication concentration (MBEC) assays and an in vivo model of chronic biofilm infection to demonstrate the biofilm-disrupting effects of an alginate oligomer, OligoG CF-5/20. Biofilm infections were established in mice by tracheal instillation of a mucoid clinical isolate of Pseudomonas aeruginosa embedded in alginate polymer beads. The disruption of the biofilm by OligoG CF-5/20 was observed in a dose-dependent manner over 24 h, with up to a 2.5-log reduction in CFU in the infected mouse lungs. Furthermore, in vitro assays showed that 5% OligoG CF-5/20 significantly reduced the MBEC for colistin from 512 μg/ml to 4 μg/ml after 8 h. These findings support the potential for OligoG CF-5/20 as a biofilm disruption agent which may have clinical value in reducing the microbial burden in chronic biofilm infections.
authors.affiliation: Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Denmark Department of Immunology and Microbiology, Costerton Biofilm Center, University of Copenhagen, Denmark whz2009@hotmail.com.
authors.forename: Wang
authors.initials: W
authors.lastname: Hengzhuang
authors.affiliation: Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Denmark.
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Song
authors.affiliation: Department of Immunology and Microbiology, Costerton Biofilm Center, University of Copenhagen, Denmark.
authors.forename: Oana
authors.initials: O
authors.lastname: Ciofu
authors.affiliation: AlgiPharma AS, Sandvika, Norway.
authors.forename: Edvar
authors.initials: E
authors.lastname: Onsøyen
authors.affiliation: AlgiPharma AS, Sandvika, Norway.
authors.forename: Philip D
authors.initials: PD
authors.lastname: Rye
authors.affiliation: Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Denmark Department of Immunology and Microbiology, Costerton Biofilm Center, University of Copenhagen, Denmark.
authors.forename: Niels
authors.initials: N
authors.lastname: Høiby
mesh_terms: D000818:Animals; D018441:Biofilms / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology*; D003091:Colistin / Q000494:pharmacology*; D005260:Female; D053582:Interleukin-1alpha / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000378:metabolism / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000378:metabolism
chemical_list: D053582:Interleukin-1alpha; D002939:Ciprofloxacin; D003091:Colistin
references.citation: J Dent. 2013 Oct;41(10):892-9
references.pmid: 23907083
references.citation: Infect Immun. 2005 Apr;73(4):2504-14
references.pmid: 15784597
references.citation: Antimicrob Agents Chemother. 2007 Oct;51(10):3677-87
references.pmid: 17620382
references.citation: APMIS. 1995 May;103(5):367-74
references.pmid: 7654361
references.citation: Science. 1999 May 21;284(5418):1318-22
references.pmid: 10334980
references.citation: J Antimicrob Chemother. 2001 Sep;48(3):391-6
references.pmid: 11533004
references.citation: Methods Mol Biol. 2014;1147:239-54
references.pmid: 24664838
references.citation: EMBO J. 2003 Aug 1;22(15):3803-15
references.pmid: 12881415
references.citation: Acta Pathol Microbiol Scand C. 1977 Apr;85(2):107-14
references.pmid: 404841
references.citation: Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):541-50
references.pmid: 4153350
references.citation: Clin Microbiol Infect. 2015 May;21 Suppl 1:S1-25
references.pmid: 25596784
references.citation: APMIS Suppl. 1992;28:1-79
references.pmid: 1449848
references.citation: Am J Respir Cell Mol Biol. 2014 Mar;50(3):483-92
references.pmid: 24074505
references.citation: J Clin Microbiol. 1999 Jun;37(6):1771-6
references.pmid: 10325322
references.citation: Antimicrob Agents Chemother. 2011 Sep;55(9):4469-74
references.pmid: 21670181
references.citation: J Bacteriol. 2001 Sep;183(18):5395-401
references.pmid: 11514525
references.citation: APMIS. 1990 Mar;98(3):203-11
references.pmid: 2107827
references.citation: Antimicrob Agents Chemother. 2012 May;56(5):2683-90
references.pmid: 22354300
references.citation: Biofouling. 2013;29(4):413-21
references.pmid: 23574333
references.citation: Nature. 2013 Jun 13;498(7453):224-7
references.pmid: 23708968
references.citation: Antimicrob Agents Chemother. 2012 Oct;56(10):5134-41
references.pmid: 22825116
references.citation: J Med Microbiol. 2003 Sep;52(Pt 9):731-40
references.pmid: 12909647
references.citation: J Antimicrob Chemother. 2006 Feb;57(2):306-11
references.pmid: 16396919